Abstract
CD33 (Siglec-3) is expressed on most acute myeloid leukemia (AML) cells and is currently being exploited as a therapeutic target. The purpose of this study was to investigate the expression pattern and potential utility of the seven recently described CD33-related siglecs as markers in AML. Besides CD33, Siglec-9 was the most highly expressed, particularly on AML cells with features of monocytic differentiation that also expressed Siglecs-5 and -7. Siglec-9 was absent from normal bone marrow myeloid progenitors but present on monocytic precursors. Using primary AML cells or transfected rat basophilic leukemia cells, Siglec-9 mediated rapid endocytosis of anti-Siglec-9 mAb. In contrast to CD33 and Siglec-5, levels of soluble Siglec-9 were low or undetectable in bone marrow plasma from AML patients and serum from normal donors. These features suggest that Siglec-9 provides not only a useful marker for certain subsets of AML, but also a potential therapeutic target.
Original language | English |
---|---|
Pages (from-to) | 211-20 |
Number of pages | 10 |
Journal | Leukemia Research |
Volume | 31 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2007 |
Keywords
- Acute Disease
- Antigens, CD
- Antigens, Differentiation, Myelomonocytic
- Flow Cytometry
- Hematopoietic Stem Cells
- Humans
- Lectins
- Leukemia, Myeloid
- Sialic Acid Binding Ig-like Lectin 3
- Sialic Acid Binding Immunoglobulin-like Lectins
- Tumor Markers, Biological